-
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
-
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
-
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
-
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
